Clinical Trial Update: An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) [Phase 3]

View source ↗

Summary

This is an open-label extension study for Treprostinil Palmitil Inhalation Powder (TPIP) in participants with pulmonary hypertension associated with interstitia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Pulmonary Hypertension

Drugs mentioned

• Treprostinil Palmitil Inhalation Powder (treprostinil palmitil)

Snippet

Sponsor: Insmed Incorporated | Conditions: Pulmonary Hypertension, Interstitial Lung Disease | Phase 3 | Status: NOT_YET_RECRUITING